Predictive value of loci in VEGF pathway genes in bevacizumab treatment
Menée sur 154 patients atteints d'un adénocarcinome métastatique du pancréas et inclus dans l'essai AViTA, ainsi que 110 patients atteints d'un carcinome rénal métastatique et inclus dans l'essai AVOREN, cette étude identifie un polymorphisme à simple nucléotide du gène VEGFR1 associé à la réponse au bevacizumab
VEGF pathway genes are highly polymorphic, with multiple common single nucleotide polymorphisms (SNPs) in regulatory regions able to affect function or expression of proteins and to alter risk and prognosis of various diseases that are tightly regulated by angiogenesis. Recently, this genetic variability has been studied as a potential predictive biomarker of outcome in patients treated with bevacizumab in colorectal, breast, and ovarian cancer. All these studies described an association betwe ...
The Lancet Oncology , commentaire, 2011